Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer

Hyunjoo Lee, Sun Och Yoon, Woon Yong Jeong, Han Kyeom Kim, Aeree Kim, Baek Hui Kim

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The polycomb group proteins have recently captured the attention of cancer biologists. enhancer of zeste homologue 2 (EZH2) and B lymphoma Mo-MLV insertion region 1 homolog (BMI-1) are the best-characterized polycomb group proteins; their deregulation contributes to the development of many malignancies including gastric cancers. H3 trimethylation at lysine 27 and DNA methylase DNA methyltransferase 3B proteins are associated with the recruitment of polycomb group proteins. Overexpression of polycomb group proteins is associated with poor prognoses in some types of cancers but with favorable prognoses in others. In the present study, we investigated the expression of the polycomb group proteins EZH2 and BMI-1 and the associated proteins H3 trimethylation at lysine 27 and DNA methyltransferase 3B in advanced gastric cancers. Based on immunohistochemical detection, we evaluated the clinical relevance of these proteins in 178 cases of advanced gastric cancers that were managed with radical surgery and adjuvant systemic chemotherapy. BMI-1, enhancer of zeste homologue 2, H3 trimethylation at lysine 27, and DNA methyltransferase 3B proteins were overexpressed in the nuclei of gastric carcinoma compared with adjacent nonneoplastic gastric parenchyma. The high-level expression of BMI-1, enhancer of zeste homologue 2, H3 trimethylation at lysine 27, and DNA methyltransferase 3B proteins were frequently noted in advanced gastric cancer tissues (70.8%, 92.1%, 58.4%, and 64.6% of cases, respectively) and well intercorrelated in expression (P <.05). The expression level of BMI-1, enhancer of zeste homologue 2, and DNA methyltransferase 3B showed correlation with sex, gross type, and histologic type of the tumor among clinicopathologic variables. In terms of patient survival, low-level expression of enhancer of zeste homologue 2 was associated with cancer-related death (P =.018) and shorter overall survival (P =.005). Low-level expression of enhancer of zeste homologue 2 may represent a negative prognostic marker (P =.005) and indicate high risk in patients with advanced gastric cancer after surgery and adjuvant chemotherapy.

Original languageEnglish
Pages (from-to)1704-1710
Number of pages7
JournalHuman Pathology
Volume43
Issue number10
DOIs
Publication statusPublished - 2012 Oct 1

Fingerprint

Polycomb-Group Proteins
Stomach Neoplasms
Lysine
Neoplasms
Adjuvant Chemotherapy
Proteins
Stomach
Survival
Enhancer of Zeste Homolog 2 Protein
Lymphoma
DNA methyltransferase 3B
Carcinoma

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Lee, Hyunjoo ; Yoon, Sun Och ; Jeong, Woon Yong ; Kim, Han Kyeom ; Kim, Aeree ; Kim, Baek Hui. / Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer. In: Human Pathology. 2012 ; Vol. 43, No. 10. pp. 1704-1710.
@article{4f26bf0bbcaa4ee694b74bca9f4868ce,
title = "Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer",
abstract = "The polycomb group proteins have recently captured the attention of cancer biologists. enhancer of zeste homologue 2 (EZH2) and B lymphoma Mo-MLV insertion region 1 homolog (BMI-1) are the best-characterized polycomb group proteins; their deregulation contributes to the development of many malignancies including gastric cancers. H3 trimethylation at lysine 27 and DNA methylase DNA methyltransferase 3B proteins are associated with the recruitment of polycomb group proteins. Overexpression of polycomb group proteins is associated with poor prognoses in some types of cancers but with favorable prognoses in others. In the present study, we investigated the expression of the polycomb group proteins EZH2 and BMI-1 and the associated proteins H3 trimethylation at lysine 27 and DNA methyltransferase 3B in advanced gastric cancers. Based on immunohistochemical detection, we evaluated the clinical relevance of these proteins in 178 cases of advanced gastric cancers that were managed with radical surgery and adjuvant systemic chemotherapy. BMI-1, enhancer of zeste homologue 2, H3 trimethylation at lysine 27, and DNA methyltransferase 3B proteins were overexpressed in the nuclei of gastric carcinoma compared with adjacent nonneoplastic gastric parenchyma. The high-level expression of BMI-1, enhancer of zeste homologue 2, H3 trimethylation at lysine 27, and DNA methyltransferase 3B proteins were frequently noted in advanced gastric cancer tissues (70.8{\%}, 92.1{\%}, 58.4{\%}, and 64.6{\%} of cases, respectively) and well intercorrelated in expression (P <.05). The expression level of BMI-1, enhancer of zeste homologue 2, and DNA methyltransferase 3B showed correlation with sex, gross type, and histologic type of the tumor among clinicopathologic variables. In terms of patient survival, low-level expression of enhancer of zeste homologue 2 was associated with cancer-related death (P =.018) and shorter overall survival (P =.005). Low-level expression of enhancer of zeste homologue 2 may represent a negative prognostic marker (P =.005) and indicate high risk in patients with advanced gastric cancer after surgery and adjuvant chemotherapy.",
author = "Hyunjoo Lee and Yoon, {Sun Och} and Jeong, {Woon Yong} and Kim, {Han Kyeom} and Aeree Kim and Kim, {Baek Hui}",
year = "2012",
month = "10",
day = "1",
doi = "10.1016/j.humpath.2011.12.019",
language = "English",
volume = "43",
pages = "1704--1710",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "10",

}

Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer. / Lee, Hyunjoo; Yoon, Sun Och; Jeong, Woon Yong; Kim, Han Kyeom; Kim, Aeree; Kim, Baek Hui.

In: Human Pathology, Vol. 43, No. 10, 01.10.2012, p. 1704-1710.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer

AU - Lee, Hyunjoo

AU - Yoon, Sun Och

AU - Jeong, Woon Yong

AU - Kim, Han Kyeom

AU - Kim, Aeree

AU - Kim, Baek Hui

PY - 2012/10/1

Y1 - 2012/10/1

N2 - The polycomb group proteins have recently captured the attention of cancer biologists. enhancer of zeste homologue 2 (EZH2) and B lymphoma Mo-MLV insertion region 1 homolog (BMI-1) are the best-characterized polycomb group proteins; their deregulation contributes to the development of many malignancies including gastric cancers. H3 trimethylation at lysine 27 and DNA methylase DNA methyltransferase 3B proteins are associated with the recruitment of polycomb group proteins. Overexpression of polycomb group proteins is associated with poor prognoses in some types of cancers but with favorable prognoses in others. In the present study, we investigated the expression of the polycomb group proteins EZH2 and BMI-1 and the associated proteins H3 trimethylation at lysine 27 and DNA methyltransferase 3B in advanced gastric cancers. Based on immunohistochemical detection, we evaluated the clinical relevance of these proteins in 178 cases of advanced gastric cancers that were managed with radical surgery and adjuvant systemic chemotherapy. BMI-1, enhancer of zeste homologue 2, H3 trimethylation at lysine 27, and DNA methyltransferase 3B proteins were overexpressed in the nuclei of gastric carcinoma compared with adjacent nonneoplastic gastric parenchyma. The high-level expression of BMI-1, enhancer of zeste homologue 2, H3 trimethylation at lysine 27, and DNA methyltransferase 3B proteins were frequently noted in advanced gastric cancer tissues (70.8%, 92.1%, 58.4%, and 64.6% of cases, respectively) and well intercorrelated in expression (P <.05). The expression level of BMI-1, enhancer of zeste homologue 2, and DNA methyltransferase 3B showed correlation with sex, gross type, and histologic type of the tumor among clinicopathologic variables. In terms of patient survival, low-level expression of enhancer of zeste homologue 2 was associated with cancer-related death (P =.018) and shorter overall survival (P =.005). Low-level expression of enhancer of zeste homologue 2 may represent a negative prognostic marker (P =.005) and indicate high risk in patients with advanced gastric cancer after surgery and adjuvant chemotherapy.

AB - The polycomb group proteins have recently captured the attention of cancer biologists. enhancer of zeste homologue 2 (EZH2) and B lymphoma Mo-MLV insertion region 1 homolog (BMI-1) are the best-characterized polycomb group proteins; their deregulation contributes to the development of many malignancies including gastric cancers. H3 trimethylation at lysine 27 and DNA methylase DNA methyltransferase 3B proteins are associated with the recruitment of polycomb group proteins. Overexpression of polycomb group proteins is associated with poor prognoses in some types of cancers but with favorable prognoses in others. In the present study, we investigated the expression of the polycomb group proteins EZH2 and BMI-1 and the associated proteins H3 trimethylation at lysine 27 and DNA methyltransferase 3B in advanced gastric cancers. Based on immunohistochemical detection, we evaluated the clinical relevance of these proteins in 178 cases of advanced gastric cancers that were managed with radical surgery and adjuvant systemic chemotherapy. BMI-1, enhancer of zeste homologue 2, H3 trimethylation at lysine 27, and DNA methyltransferase 3B proteins were overexpressed in the nuclei of gastric carcinoma compared with adjacent nonneoplastic gastric parenchyma. The high-level expression of BMI-1, enhancer of zeste homologue 2, H3 trimethylation at lysine 27, and DNA methyltransferase 3B proteins were frequently noted in advanced gastric cancer tissues (70.8%, 92.1%, 58.4%, and 64.6% of cases, respectively) and well intercorrelated in expression (P <.05). The expression level of BMI-1, enhancer of zeste homologue 2, and DNA methyltransferase 3B showed correlation with sex, gross type, and histologic type of the tumor among clinicopathologic variables. In terms of patient survival, low-level expression of enhancer of zeste homologue 2 was associated with cancer-related death (P =.018) and shorter overall survival (P =.005). Low-level expression of enhancer of zeste homologue 2 may represent a negative prognostic marker (P =.005) and indicate high risk in patients with advanced gastric cancer after surgery and adjuvant chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84866503477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866503477&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2011.12.019

DO - 10.1016/j.humpath.2011.12.019

M3 - Article

C2 - 22520951

AN - SCOPUS:84866503477

VL - 43

SP - 1704

EP - 1710

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 10

ER -